genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2020
Ablynx
Coronavirus
Camelid Nanobodies Poised to Revolutionize Antibody Therapeutics
Industry News
Ablynx, Protagonist Report Phase II Failures
Drug Discovery
Sanofi to Acquire Ablynx for $4.8B
News
Ablynx Granted $2.3M to Advance Nanobody Development
Cancer
Ablynx Earns $3M from Pfizer as Second Anti-TNF-Alpha Nanobody Enters Clinic
News
Ablynx Receives €3M Milestone from BI and Starts Phase II Study with In-House Nanobody
Drug Discovery
Ablynx Awarded €1.5M to Advance Nanobody Development
News
Merck Serono Pays $14.4M Upfront in Deal with Ablynx
Scroll Up
Scroll Up
